诉讼基本信息 - 律师事务所Kessler Topaz Meltzer & Check, LLP宣布已对萤火虫航空航天公司提起证券集体诉讼 [1] - 诉讼代表在2025年8月7日左右进行的公司IPO中，根据和/或可追溯至相关注册声明及招股书购买萤火虫普通股的投资者 [1] - 诉讼亦代表在2025年8月7日至2025年9月29日期间购买公司证券的投资者 [1] - 首席原告截止日期为2026年1月12日 [1] 指控内容 - 指控称在招股文件及整个集体诉讼期间被告做出了虚假和/或误导性陈述及/或未能披露 [2] - 具体指控包括萤火虫高估了其航天器解决方案产品的需求及增长前景 [2] - 具体指控包括阿尔法火箭项目未达到其声称的操作准备状态和商业可行性 [2] - 指控称因此被告关于公司业务运营和前景的陈述在所有相关时间均存在重大虚假误导和/或缺乏合理依据 [2]

收购要约核心信息 - 灵北制药向Avadel Pharmaceuticals提出价值高达24亿美元的主动收购要约 每股报价23美元 其中21美元为现金 2美元为或有价值权利[2] - 此前 Alkermes已与Avadel达成价值21亿美元的收购协议 每股价值最高20美元 包括18.50美元现金和最高1.50美元的或有价值权利[2] - Avadel公司宣布灵北制药的要约为"更优方案" 其股价在早盘交易中飙升超过20%至23.16美元 而Alkermes股价下跌超过6%至29美元[4] 潜在收购方财务与策略分析 - Alkermes拥有11亿美元现金 无债务 EBITDA为3.8亿美元 其内部交易能力为27亿美元[5] - 灵北制药拥有5.5亿美元现金 债务19亿美元 EBITDA为13亿美元 其理论交易能力为38亿美元 表面上有能力出价高于Alkermes[5] - Alkermes可能采取灵北制药无法使用的策略 即发行股权来增强竞购能力[6] - 灵北制药的或有价值权利与销售里程碑挂钩 Alkermes也可采取类似结构 其现有或有价值权利仅与Lumryz在特发性嗜睡症患者中的获批相关[6] 目标公司产品与市场前景 - Avadel Pharmaceuticals专注于发作性睡病治疗 其药物Lumryz适用于7岁及以上因发作性睡病引起的日间嗜睡患者[3] - Alkermes正在测试其他发作性睡病治疗方法 可能与Avadel的Lumryz及实验性药物valiloxybate形成良好互补[3] - 分析师指出灵北制药交易中的销售里程碑较为激进 要求Lumryz和valiloxybate在2027年12月31日前任何一年美国销售额合计至少达到4.5亿美元 并在2030年12月31日前达到7亿美元[7] - 有分析师预估Lumryz在2027年的销售额为3.99亿美元 到2030年为5.81亿美元 而更广泛的分析师预期该发作性睡病药物销售额分别为4.49亿美元和4.59亿美元[7]

Under Dr. Niethammer's leadership, Vaximm will focus on integrating its anti-angiogenic immune activation platform with complementary viral oncolysis technologies that have already achieved clinical proof-of-concept (PoC) in a completed U.S. FDA Phase 2a study, through a forthcoming strategic collaboration to be announced in the coming months. The collaboration aims to build a next-generation immuno-oncology platform leveraging synergistic mechanisms of action for renal cell carcinoma (RCC) and other advanc ...

I've held tentative optimism about the Autolus Therapeutics plc ( AUTL ) investment thesis for some time now, despite the market and company-specific risks posed by bringing another CD19 cell therapy to market. Indeed, theI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pit ...

I've held tentative optimism about the Autolus Therapeutics plc ( AUTL ) investment thesis for some time now, despite the market and company-specific risks posed by bringing another CD19 cell therapy to market. Indeed, theI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pit ...

PresentationJonas Söderström Welcome, everyone, to the BioStock Studio where we today are doing this live webcast. Thank you for tuning in. So we are meeting today in the context of the World Diabetes Day. It's a day to raise awareness about diabetes, type 1 diabetes and also the impact that this disease has on people's lives. Around 9 million people globally are living with type 1 diabetes. And each year, roughly 300,000 to 500,000 people are newly diagnosed with it globally. So it is a big, big medical ne ...

Accessibility StatementSkip Navigation James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi & Faruqi, LLP) Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. According to the complaint, defendants made materially false and misleading statements regarding the timeline for the New Drug Application ("NDA" ...

Accessibility StatementSkip Navigation We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes. Contacts Ademi & Fruchter LLP Guri AdemiToll Free: (866) 264-3995Fax: (414) 482-8001 SOURCE Ademi LLP 21% MILWAUKEE, Nov. 14, 2025 /PRNewswire/ -- The Ademi Firm is investigating Cidara (Nasdaq: CDTX) for possible breaches of fiduciary duty and oth ...

SAN DIEGO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Soleno Therapeutics, Inc. (NASDAQ: SLNO) focused on whether Soleno and certain of its executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the Soleno investigation or if you are a Soleno investor who suffered a loss and would like to ...

BREAKING: Futures Fall After Growth-Led Market Sell-Off Cidara Therapeutics (CDTX) shares doubled, and then some, on Friday after Merck (MRK) agreed to buy the biotech company for $9.2 billion. YOU MAY ALSO LIKE: Bristol Myers Slumps After Its Heart Condition Study Gets The Boot Avadel Surges 20% On Lundbeck's Surprise Alkermes-Topping Bid Looking For The Next Big Stock Market Winners? Start With These 3 Steps Want More IBD Insights? Subscribe To Our Investing Podcast! The deal is "nothing to sneeze at," RB ...